Many of the advances in personalized medicine we have witnessed in recent years have been driven by disruptive technologies, the invention of high-throughput DNA sequencers being key among them. For example, the first human genome to be sequenced cost a whopping $2.7 billion and took nearly 13 years to complete, a major roadblock toward using the technology to develop medicines targeting an individual’s unique genetic makeup. The introduction of next-generation sequencing (NGS) lowered the cost dramatically to a mere $100,000 by 2009. By 2014, the price had shrunk even further to a manageable $1,000 per patient.
So what’s up next for NGS? We ask our panelists, whose companies were founded on the basis of the technology:
Amanda Cashin, PhD, Co-Founder and Head, Illumina Accelerator
Justin Kao, Co-Founder and Senior Vice President of Business Development and Partnerships, Helix
Pieter van Rooyen, PhD, President and Chief Executive Officer, Edico Genome
MODERATOR: Ashley Van Zeeland, PhD, MBA, Chief Technology Officer, Human Longevity, Inc.